Personalised medicine is in the news more-and-more often these days, with its goal of giving the right treatment to the right patient at the right time.
Breakthroughs in genetics, calls for more and better screening, developments in imaging techniques and the emergence of what we now call ‘Big Data’ have already changed the world of healthcare for ever.
The theme of the European Alliance for Personalised Medicine’s 3rd annual Congress, under the auspices of the Finnish Presidency of the EU, will be “Forward together with innovation: The importance of policy making in the era of personalised medicine.”
High-level speakers and attendees will come from a wide range of stakeholder groups including patients, healthcare professionals, academics, industry representatives, politicians and legislators, the media and more.
The event will be held in Brussels, from 03-04 December, and the Belgian capital has been chosen to host the event as the new Parliament will be in place after the May European elections, while the next European Commission will also, by then, be in the Berlaymont under its new president.
Brexit may even have come to a conclusion by early December, who knows? But it will certainly be among the major talking points.
As such, the Congress will be held in Brussels, which will be at the heart of all the ‘action’.
Congress will showcase different objectives which both the public and private sector can support, with a view to allowing the EU to present a common objective.
Innovation and the incentives for it are key to health and wealth in the current EU, and EAPM is sure that its 3rd annual Congress will move Europe forward in this regard.
As always, one of the goals of Congress will be to engage politicians and lawmakers in the fast-growing field of personalised medicine, and deliver political asks through our consensus-based process.
Europe needs to grasp the fact that health equals wealth and that investment in research and in-novation, alongside laws and rules that are fit-for-purpose and reflect the swiftly changing world of medicine, are vital.
Hence our continued interaction with MEPs, Commissioners and Member State health leaders, alongside all stakeholders striving to move personalised
We hope to see you in Brussels in December.
David Byrne and Gordon McVie, EAPM Co-Chairs
Denis Horgan – Executive Director EAPM